Expertise in
33
conditions

Dr. Vamsi Vasireddy

Hematology | Oncology
Carle Foundation Hospital
509 W University Ave, 
Urbana, IL 
Offers Telehealth
Expertise in
33
conditions
Carle Foundation Hospital
509 W University Ave, 
Urbana, IL 

Overview

Vamsi Vasireddy is a Hematologist and an Oncologist practicing medicine in Urbana, Illinois.

Dr. Vasireddy is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), Urothelial Cancer, and Nephrectomy.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 40 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

Carle Hoopeston Regional Health Center
Kirby Medical Center
Carle Bromenn Medical Center
Crawford Memorial Hospital
Carle Foundation Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Carle Foundation Hospital
509 W University Ave, Urbana, IL 61801
Other Locations
Carle
602 W University Ave, Urbana, IL 61801
Carle Cancer Center
509 W University Ave, Urbana, IL 61801

Additional Areas of Focus

Dr. Vasireddy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Radiation, Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Docetaxel
Study Phase: Phase 2
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Lomustine, Temozolomide
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study.
Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study.
Journal: Cancers
Published: November 27, 2024
Similar Doctors
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Referral may be required

Carle Foundation Hospital

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
309-624-9856
Languages Spoken:
English
See accepted insurances

Connie Piccone is a Hematologist and an Oncologist practicing medicine in Urbana, Illinois. Dr. Piccone is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Gallbladder Removal.

Expertise in
113
conditions
Dr. Pankaj Kumar
Hematology | Oncology | Internal Medicine
Expertise in
113
conditions
Dr. Pankaj Kumar
Hematology | Oncology | Internal Medicine
Referral may be required

Illinois Cancercare, PC

3105 Magory Dr, 
Bloomington, IL 
 (45.1 miles away)
Languages Spoken:
English
See accepted insurances

Pankaj Kumar is a Hematologist and an Oncologist practicing medicine in Bloomington, Illinois. Dr. Kumar is highly rated in 113 conditions, according to our data. His clinical expertise encompasses Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, Severe Congenital Neutropenia, and Parathyroidectomy. Dr. Kumar is board certified in American Board Of Internal Medicine.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Carle

602 W University Ave, 
Urbana, IL 
 (0.1 miles away)
217-383-3010
Languages Spoken:
English
See accepted insurances

Kendrith Rowland is an Oncologist practicing medicine in Urbana, Illinois. Dr. Rowland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Colorectal Cancer, Paget Disease of the Breast, and Angiosarcoma.

Frequently Asked Questions about Dr. Vamsi Vasireddy

How do I make an appointment with Dr. Vamsi Vasireddy?

You can book an appointment with Dr. Vamsi Vasireddy by calling their office at 217-383-3311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vamsi Vasireddy a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vamsi Vasireddy is classified as an Distinguished expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vamsi Vasireddy specialize in?

While Dr. Vamsi Vasireddy is a Hematology, they have specific expertise in Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vamsi Vasireddy participate in research or clinical trials?

Yes. Dr. Vamsi Vasireddy has published 6 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Dr. Vamsi Vasireddy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vamsi Vasireddy accept my insurance?

Dr. Vamsi Vasireddy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 217-383-3311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasireddy's expertise for a condition
ConditionClose
    View All 29 Advanced Conditions
    View All 95 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile